India's Symbiotec Pharmalab profit falls 53% in Q1
Shares of Symbiotec Pharmalab declined 3.11% to 1,120.10 rupees after the company reported a 53% drop in its first-quarter net profit to 141.56 million rupees ($1.48 million) compared to the previous year. Revenue from operations rose to 2.18 billion rupees from 2.03 billion rupees. Analysts at ICICI Direct Research cited expenses from new businesses as the main drag on EBITDA.
10 rupees after the company reported its first results since its IPO. The stock could end a run of three straight sessions of gains. 48 million). 03 billion rupees in the year-ago period.
Analysts at ICICI Direct Research said EBITDA was weighed by costs from new businesses that have yet to generate significant traction. 4% since their trading debut on September 1. com; (+91) 8296756080)